Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S393000
Reexamination Certificate
active
07875617
ABSTRACT:
The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.
REFERENCES:
patent: 5407823 (1995-04-01), Sokoloff et al.
patent: 5872119 (1999-02-01), Wermuth et al.
patent: 6828325 (2004-12-01), Feenstra et al.
patent: 0 189 612 (1985-12-01), None
patent: 0 189 612 (1986-08-01), None
patent: 0 900 792 (1999-03-01), None
patent: WO-92/07937 (1992-05-01), None
patent: WO-03/028728 (2003-04-01), None
patent: WO-2004/084952 (2004-10-01), None
Le Foll, et al., Neuroadaptations to Hyperdopaminergia in Dopamine D3 Receptor-deficient Mice, Life Sciences, 76, 1281-1296 (2005).
Garrido Fabrice
Mann Andre
Pilon Catherine
Schoenfelder Angele
Sokoloff Pierre
Institut National de la Sante et de la Recherche Medicale (INSER
Leeser Erich A
Schulman B. Aaron
Stites & Harbison PLLC
Wilson James O
LandOfFree
3,4-dihydro-2-naphthamide derivatives as selective dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,4-dihydro-2-naphthamide derivatives as selective dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-dihydro-2-naphthamide derivatives as selective dopamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679079